2018 World Conference on Lung Cancer Reports Energize Attendees

Posted by ALCF Staff on October 9th, 2018

Bonnie Addario leads a panel discussion “Patients and Advocacy Driving Research Together” with Dr. Fred Hirsch (Physician), Dr Idiko Medve (Survivor) , Dr Ignatius Ou (Physician), Merel Hennink (Survivor) and Dr Paul Wheatley-Price (Physician).

Leaders from ALCMI and ALCF recently attended the 2018 World Conference on Lung Cancer in Toronto. It was a banner year, with nearly 7,500 attendees from around the globe sharing the latest updates and advances in lung cancer research and treatment. There was a palpable energy and enthusiasm among participants. Highlighting the progress made in the field, four of the conference presentations coincided with publication in the New England Journal of Medicine.

Among the many exciting findings presented at the conference:

  • Results from the PACIFIC study showed that durvalumab leads to meaningful improvements in overall survival for patients with Stage III, unresectable non-small cell lung cancer (NSCLC) who have not progressed following chemoradiotherapy.
  • The ALTA-1L study showed that first-line brigatinib improves progression-free survival in treatment-naïve ALK+ NSLCL patients with advanced disease.
  • Results from the KEYNOTE-407 study found that pembrolizumab plus chemotherapy significantly prolongs overall survival and progression-free survival among patients with untreated metastatic squamous NSCLC.
  • The imPOWER133 study found that the addition of the PD-L1 inhibitor, atezolizumab, to carboplatin and etoposide provides a significant improvement in overall and progression-free survival in first-line management of extensive stage small cell lung cancer (ES-SCLC). This marks the first major advance in SCLC in two decades.
  • The NELSON screening study found a 26% reduction in mortality in at-risk males, paving the way for rollout of low-dose CT screening in Europe.
  • Dacomitinib has received FDA approval for first-line treatment of patients with metastatic NSCLC with EGFR exon 19 deletion or exon 21 L858R substitution mutations.

For more on this year’s meeting, also check out the Lung Cancer Alliance update article.

Comments are closed.